separation typically fell within the range that has been reported for successful engraftment by bone marrow cells. Another observation of practical importance is that procedures to remove erythrocytes or granulocytes prior to freezing, and washing of thawed cells before plating, entailed large losses of progenitor cells, the yield of unwashed progenitor cells from unfractionated cord blood being many times greater. The provisional inference is that human umbilical cord blood from a single individual is typically a sufficient source of cells for autologous (syngeneic) and for major histocompatibility complex-matched allogeneic hematopoietic reconstitution.
Circulating blood cells are derived and replaced by a catenated system originating from hematopoietic stem and progenitor cells, recognized mostly by functional tests rather than by morphology (1) (2) (3) (4) . The primary site of production of stem/progenitor cells in human adults is the bone marrow (1, 2) . Hence autologous or major histocompatibility complexmatched bone marrow transplantation is the usual therapeutic vehicle for hematopoietic reconstitution. Although adult blood has had some use as an alternative source (5) , in practice the content of stem/progenitor cells is so low (1, 2) that multiple leukopheresis is necessary and has been reported primarily in patients undergoing intense temporary rebound hematopoiesis resulting from recent chemotherapy (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) .
In human ontogeny, hematopoietic stem/progenitor cells occur first in the yolk sac, later in fetal liver, and then in fetal bone marrow (1, 17) , and transplantation of fetal liver cells has been used in a limited setting to correct hematopoietic deficiencies (18, 19) . Stem/progenitor cells occur in fetal blood (1, 17) , and human umbilical cord blood contains stem cells (20, 21) , so called because in colony assay in vitro they exhibit replating efficiency indicative of self-renewal, as well as multipotential (CFU-GEMM), erythroid (BFU-E), and granulocyte-macrophage (CFU-GM) progenitor cells (20) (21) (22) (23) (24) (25) (26) . The frequency of cord-blood progenitors (no. of colonies formed/no. of cells plated) equals or exceeds that of marrow and greatly surpasses that of adult blood. Progenitor cells from human umbilical cord blood can be maintained for many weeks in long-term liquid culture systems, suggesting their production from more primitive cells (22, 27) .
The use of human umbilical cord blood for therapeutic reconstitution was proposed by one of us (E.A.B., unpublished work), who subsequently observed successful hematopoietic reconstitution oflethally irradiated inbred mice with syngeneic neonatal blood. The prospect of storing cord blood cells (normally discarded) for potential future medical use by the donor has many advantages, notably in disposing of the need for bone marrow donors, in providing a disease-free source of hematopoietic cells, and in allowing reconstitution of patients who lack a clinically approved donor, freedom from graft-versus-host disease, and freedom from the increased mortality that may accompany nonautologous bone marrow transplantation in circumstances where the degree of accidental hematopoietic injury is uncertain (see refs. [28] [29] [30] .
The main questions addressed in the following study concern comparative determinations of the reconstituting cellular contents of cord blood and bone marrow, by measure of hematopoietic progenitor cells (31) (32) (33) (34) and the collection, transport, and optimal cryopreservation of cord blood. CFU-GM. The assay for CFU-GM was performed as described (35, 36) (38) .
BFU-E, CFU-GEMM, and CFU-GM. (vol/vol) autologous serum/culture medium was asceptically added dropwise with slight mixing between each drop until the suspension volume was doubled. This suspension was transferred to a larger tube with the dropwise addition of the 50% (vol/vol) autologous serum/culture mixture continued until a volume of 6-7 ml was reached. Diluent was then added dropwise, with mixing at every 0.5-ml increment until the volume reached 9-10 ml. Cells were pelleted by centrifugation at 4°C 200 x g for 10 min, the supernatant was aspirated off, and 1 ml of chilled 20% (vol/vol) autologous serum/ culture mixture was added dropwise with gentle mixing of the solution. An additional 4 ml of chilled serum/culture medium was added slowly. Cells were washed a second time.
In later studies, larger volumes of cells were placed without separation, concentration, or washing into freezing bags and cooled to -80°C in a liquid nitrogen programmed freezer (Cryomed, Mt. Clemens, MI) coded at an average rate of -1°C per min, as described elsewhere (41), prior to placing the bags for storage in the liquid phase of liquid nitrogen. The defrosting procedure was done without serum-containing medium as the cells were originally frozen in their own plasma.
RESULTS
Survival of Hematopoietic Progenitor Cells. Before evaluating large numbers of umbilical cord blood collections for their content of hematopoietic progenitor cells, experiments were set up to determine whether these cells could survive in cord blood with anticoagulant for up to 3 days without added exogenous growth factors. Cord blood was collected and separated into 10 tubes (2 ml each). One tube was used at time 0 for separation of cells into a low-density fraction (<1.077 gm/ml) and for plating in semisolid medium for assessing progenitor cell numbers. Three tubes each were left at 4°C, -25TC (room temperature), and 370C (in an incubator). On days 1 (t = 24 hr), 2 Table 2 ). The number of colonies stimulated by each of the CSF was less than that stimulated by CM 5637. CM 5637 contains a number of growth factors including GM-CSF and G-CSF (37) and the higher number of colonies detected with CM 5637 probably reflects additive or synergistic actions between the growth factors (43) .
Numbers of Hematopoietic Progenitor Cells. One hundred and one samples received by overnight express mail service were assessed for a number of parameters, including volume of blood collected, numbers of unfractionated nucleated cells, numbers of low-density nucleated cells, and absolute numbers of hematopoietic progenitor cells in the low-density fraction (Table 3) . Although variability was noted between cord blood samples, it was clear that cord blood contained substantial numbers of hematopoietic progenitor cells. In fact, the average number of CFU-GM collected per sample was within the lower range of numbers of CFU-GM in donor marrow that have been associated with successful autologous engraftment (32, 34) .
It became apparent, however, that the percent of cells recovered in the low-density fraction, 15.1 ± 0.9o (n = 101 samples), was much lower than was attained with adult bone marrow and circulating adult blood. This low recovery of low-density cord blood cells did not reflect the number of cells loaded on the Ficoll/Hypaque gradient, and removing set up to determine whether the density-cut procedure was also causing loss of hematopoietic progenitor cells. Progenitor cells recovered from unfractionated cord blood (set up without removal of red blood cells) were compared with numbers of progenitors isolated in the low-(<1.077 gm/ml) and high-(>1.077 gm/ml) density fractions. As few as 6-40% of the total number of day-7 and day-14 CFU-GM, BFU-E-2, BFU-E-1, and CFU-GEMM cells were recovered in the low-density fraction. The sum of progenitors in both the low-and heavy-density fractions did not equal that of the unfractionated group and was sometimes as low as 30-40% of the unfractionated blood cell number. Collecting cells with a density of <1.070 gm/ml did not improve the recovery of progenitor cells. Attempts to remove erythrocytes from unfractionated cord blood by lysis of the nonnucleated cells with ammonium chloride or by sedimenting erythrocytes by gravity, methylcellulose, or centrifugation prior to culturing them for assessment of progenitor cell numbers resulted in losses of 50-90% of With this information in mind, attempts were made to optimize the amount of cord blood collected, and also to recover blood from the placenta after the baby had been delivered. Results from three cord blood collections made in this way, which assessed progenitor cell numbers in unseparated blood, are shown in Table 4 . These studies illustrate much greater yields of nucleated and hematopoietic progenitor cells. The yields of nucleated cells recovered are well within the range of cell numbers usually used for autologous and allogeneic bone marrow transplantation, and the numbers of CFU-GM are in the upper range of the numbers of CFU-GM in donor marrows that have been associated with successful engraftment in autologous bone marrow transplantation and are in the range used for allogeneic transplantation (31) (32) (33) (34) .
Cryopreservation of Umbilical Cord Blood Cells. Twelve samples of low-density (<1.077 gm/ml) cord blood cells were frozen in small tubes in 2-ml aliquots of 8 x 106 cells using the methanol freezing technique. Cells were thawed after 1-10 months and washed twice, and viable nucleated cells were counted and plated for hematopoietic progenitor cell quantitation. The recoveries for thawed samples (mean ± SEM) of nucleated cells, day-7 and -14 CFU-GM (agar cultures), 
DISCUSSION
We see that blood collected from the umbilical cord contains CFU-GM in numbers well within the range of marrow CFU-GM that have been associated with successful autologous and major histocompatibility complex-matched allogeneic bone marrow transplantation (31) (32) (33) (34) . Although the CFU-GM is not a stem cell, but rather a lineage-restricted progenitor cell, the speed of hematologic recovery and survival of mice transplanted with bone marrow have been correlated directly with the number of CFU-GM transplanted (44) , and the CFU-GM content of human bone marrow also correlated with the rate of hematopoietic reconstitution after autologous bone marrow transplantation (45) . Cord blood BFU-E and CFU-GEMM were also within the range of these progenitors found in successful human marrow donor grafts (31) .
Unfortunately, there is not yet a direct assay for human hematopoietic repopulating cells. Pluripotential hematopoietic stem cells are defined functionally by their ability to self-renew (make more of themselves) and to give rise to blood cells of multilineages (1) . Murine colony assays in vivo detect what appear to be subsets of myeloid stem cells, the colony-forming units in spleen (CFU-S) (1, 3, 43) . Murine CFU-S have self-renewal capacity and give rise to multicell lineages, but it does not appear that the CFU-S is a marrow-repopulating cell (1, 3, 43) . The closest human equivalent to the murine CFU-S in vitro is the stem (S) cell (46, 47) . Human umbilical cord blood contains in vitro stem cells (20, 21) , which were identified in human cord blood before they were detected in human bone marrow (48) (49) (50) . The frequency of stem cells in both human cord blood and human marrow is essentially the same, but their numbers are very low (20, 21, (48) (49) (50) 
